Skip to main content Skip to main navigation menu Skip to site footer

D-dimer level differences in pneumonia patients than in COVID-19

  • Rahayu Anggraini ,
  • Eppy Setiyowati ,
  • Difran Nobel Bistara ,
  • Firdaus ,
  • Budhi Setianto ,


Introduction: Pneumonia, also known as pneumonia, is caused by inflammation of the air sacs (alveoli) in one or both lungs. In severe pneumonia, intravascular and intra-alveolar coagulation occurs, which is a response to local and systemic inflammatory processes. The clinical consequence of these changes in coagulation is an increase in the level of D-Dimer which causes death. The purpose of this study was to evaluate D-Dimer in 29 pneumonia patients and 37 COVID-19 patients at Jemursari Hospital.

Methods: This research is quantitative with a cross-sectional analytic observational method. The research sample was obtained from the Jemursari Islamic Hospital in Surabaya for pneumonia and Covid-19 patients in 2021

Results: The results of the study, a number of women more than men. In women 63,6% and in men 36,4%, while the age is 46-54 years in pneumonia patients 28% and in Covid-19 patients 30%. D-Dimer levels in pneumonia patients 1001-2000 ng/mL were 35% higher compared to COVID-19 patients 501-1000 ng/mL were 30%. Mann Whitney's non-parametric test results obtained p=0.041 (p<0.05), meaning that there was a difference in D-Dimer levels between pneumonia patients and COVID-19.

Conclusion: D-Dimer levels were more elevated in pneumonia patients than in Covid-19, so Covid-19 infection did not exacerbate coagulation and fibrinolysis activities.


  1. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macías M, Toledo-Samaniego N, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020;192.
  2. Arslan S, Ugurlu S, Bulut G, Akkurt I. The association between plasma d-dimer levels and community-acquired pneumonia. Clinics. 2010;65(6).
  3. World Health Organization. WHO | Pneumonia. Who. 2016.
  4. Saraswati R, Hakim DDL, Garna H. Kadar D-Dimer Plasma sebagai Prediktor Kematian Penderita Pneumonia Usia 2–59 Bulan. Majalah Kedokteran Bandung. 2012;44(1).
  5. Kurniawati D, Prasetyo B, Pandu H, Nurdianto AR. Clinical presentation of maternal death with COVID-19 in rural tertiary care center: A retrospective-descriptive Study. Bali Medical Journal. 2022;11(1):87–90.
  6. Minanti BR, Soelistijo SA, Pranoto A. Characteristic profiles of patients with diabetes mellitus and COVID-19 during the second epidemic wave in East Java, Indonesia: a retrospective study. Bali Medical Journal. 2023;12(1):1120–6. Available from:
  7. Yu B, Li X, Chen J, Ouyang M, Zhang H, Zhao X, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis. 2020;50(3).
  8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020;18(4).
  9. Durmaz N, Selçuk Duru N, Elevli M, Çivilibal M, Şahin K. Evaluation of Serum D-dimer Levels in Children with Pneumonia. Haseki Tıp Bülteni. 2016;54(1).
  10. Gungor B, Atici A, Baycan OF, Alici G, Ozturk F, Tugrul S, et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis. Vol. 39, American Journal of Emergency Medicine. 2021.
  11. Rahman S, Yusuf M, Rizal S, Amirsyah M, Pratama R. Risk assessment for surgeries during covid-19 pandemic in dr. Zainoel abidin hospital, banda aceh, indonesia. Bali Medical Journal. 2021;10(1):387–91.
  12. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020;195.
  13. Güneysel O, Pirmit S, Karakurt S. Plasma d-dimer levels increase with the severity of community acquired pneumonia. Tuberk Toraks. 2004;52(4).
  14. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5).
  15. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. Vol. 323, JAMA - Journal of the American Medical Association. 2020.

How to Cite

Anggraini, R., Setiyowati, E. ., Bistara, D. N. ., Firdaus, & Setianto, B. . (2023). D-dimer level differences in pneumonia patients than in COVID-19. Bali Medical Journal, 12(3), 2828–2831.




Search Panel